3.8 Article

Adverse events associated with Covishield vaccination among healthcare workers in a tertiary hospital in South India

期刊

VACCINE: X
卷 12, 期 -, 页码 -

出版社

ELSEVIER
DOI: 10.1016/j.jvacx.2022.100210

关键词

-

资金

  1. Pharmacovigilance program of India, Indian Pharma copoeia commission, Ghaziabad

向作者/读者索取更多资源

This study aimed to evaluate the safety of the Covishield vaccine among healthcare workers and the factors associated with adverse events. The results showed that the vaccination was safe and well tolerated, with adverse reactions mainly occurring on the first and second days after vaccination, and younger individuals and females were more likely to experience systemic symptoms.
Background: Vaccination is the most important prophylactic measure taken to curb COVID-19 pandemics. This study was undertaken to throw light on the safety of Covishield vaccine among health care workers (HCWs) and to assess the co-variates associated with incidence of adverse events. Methods: This prospective observational study was conducted in a tertiary care center in South India as part of the HCW vaccination drive. All consenting HCWs who received the first dose of Covishield vaccine and developed ADRs were included in this study. After vaccination, all beneficiaries were monitored for AEFI for a period of half an hour and later followed up through telephone and google survey forms on day 2 and day 7 of vaccination. The data was subsequently collated into spreadsheet format and analyzed. Results: The study included 1264 consenting healthcare workers who were predominantly youth, aged 15-24 years (n = 583, 46 %) and with a female preponderance of 76 % (n = 960). Past history of COVID-19 infections was reported among 4.6 % (58) of the study population. Postvaccination symptoms were majorly reported during the first (40 %) and second day (44 %) after vaccination with a high prevalence of both local (n = 1083, 85 %) and systemic symptoms (n = 1065, 84 %). The mean duration of symptoms was observed to be 1.4 +/- 0.81 days post vaccination. Symptoms were observed significantly high among females (76.7 %, p = 0.013). The prevalence of systemic (88 % vs 80 %) (p < 0.001) and allergic symptoms (7 % vs 3 %; p = 0.03) were observed to be significantly high among respondents with < 25 years of age. The systemic and allergic symptoms following vaccination were reported to be low among health-care workers who had a previous history of COVID-19 infection. Conclusion: COVID vaccination has been observed to be safe and well tolerated with more systemic symptoms reported among younger age group and females. (C) 2022 The Authors. Published by Elsevier Ltd.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

3.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据